S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
Sri Lanka marks independence anniversary amid economic woes
A gold storm is coming… (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
Sri Lanka marks independence anniversary amid economic woes
A gold storm is coming… (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
Sri Lanka marks independence anniversary amid economic woes
A gold storm is coming… (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
A gold storm is coming… (Ad)
Why a new Alzheimer's drug is having a slow US debut
Sri Lanka marks independence anniversary amid economic woes
A gold storm is coming… (Ad)
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
A gold storm is coming… (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
NASDAQ:IDRA

Idera Pharmaceuticals - IDRA Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
$0.17
$0.71
52-Week Range
N/A
Volume
371,800 shs
Average Volume
464,030 shs
Market Capitalization
$26.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IDRA stock logo

About Idera Pharmaceuticals (NASDAQ:IDRA) Stock

Aceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Stock News Headlines

“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Idera Pharma Acquires Rare Disease Player, Names New CEO
Idera Pharmaceuticals Acquires Aceragen
Idera Pharmaceuticals Stock (NASDAQ:IDRA), Dividends
Why Are Idera Pharmaceuticals Shares Soaring Today
Idera Pharmaceuticals Announces Tilsotolimod Updates
IDRA Nov 2021 3.000 call
See More Headlines
Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Company Calendar

Last Earnings
11/14/2022
Today
2/05/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IDRA
Employees
32
Year Founded
1989

Profitability

Net Income
$98.09 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.56 per share

Miscellaneous

Free Float
59,206,000
Market Cap
$26.50 million
Optionable
Optionable
Beta
1.25

Social Links


Key Executives

  • Mr. John J. Kirby CPAMr. John J. Kirby CPA (Age 50)
    Chief Financial Officer
    Comp: $477.41k
  • Mr. Bryant David LimMr. Bryant David Lim (Age 51)
    Chief Bus. Officer & Gen. Counsel
    Comp: $480.96k
  • Mr. John C. Taylor (Age 52)
    CEO & Director
  • Mr. Daniel Salain (Age 55)
    Chief Operating Officer
  • Mr. Andy Jordan (Age 75)
    Chief Strategy Officer
  • Dr. Carl Kraus M.D. (Age 53)
    Chief Medical Officer
  • Dr. Shah Rahimian M.D.
    Ph.D., Medical Director & Global Clinical Lead for Oncology
  • Dr. Joanna Caroline Horobin Ch.B (Age 67)
    M.B., Advisor
  • Dr. Sudhir Agrawal D.Phil. (Age 68)
    F.R.S.C., Scientific Advisor
  • Mr. Louis J. Arcudi III (Age 61)
    M.B.A., MBA, Adviser













IDRA Stock - Frequently Asked Questions

When is Idera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our IDRA earnings forecast
.

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) issued its quarterly earnings results on Monday, November, 14th. The biotechnology company reported ($0.06) EPS for the quarter.

When did Idera Pharmaceuticals' stock split?

Idera Pharmaceuticals shares split before market open on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly created shares were distributed to shareholders after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Idera Pharmaceuticals own?
What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bryant David Lim, Daniel B Soland, Elizabeth Ann Tarka, Invest Corp Pillar, John J Kirby, John J Kirby, Michael R Dougherty and Vincent Milano.
View institutional ownership trends
.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Idera Pharmaceuticals make?

Idera Pharmaceuticals (NASDAQ:IDRA) has a market capitalization of $0.00. The biotechnology company earns $98.09 million in net income (profit) each year or ($0.32) on an earnings per share basis.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The official website for the company is www.iderapharma.com. The biotechnology company can be reached via phone at (484) 348-1600, via email at jconwell@iderapharma.com, or via fax at 617-679-5592.

This page (NASDAQ:IDRA) was last updated on 2/5/2023 by MarketBeat.com Staff